AgomAb Therapeutics (NASDAQ:AGMB) Sees Large Volume Increase – Time to Buy?

AgomAb Therapeutics NV (NASDAQ:AGMB) saw an uptick in trading volume on Friday . 265,532 shares traded hands during mid-day trading, an increase of 103% from the previous session’s volume of 131,018 shares.The stock last traded at $13.8680 and had previously closed at $13.50.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on AGMB. HC Wainwright assumed coverage on shares of AgomAb Therapeutics in a research report on Monday, June 22nd. They set a “buy” rating and a $35.00 price target on the stock. B. Riley Financial began coverage on shares of AgomAb Therapeutics in a research note on Thursday, July 23rd. They issued a “buy” rating and a $34.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $33.00.

AgomAb Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.01, a current ratio of 6.52 and a quick ratio of 6.52. The company has a 50 day simple moving average of $12.18.

AgomAb Therapeutics (NASDAQ:AGMB) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share for the quarter. On average, research analysts predict that AgomAb Therapeutics NV will post -1.84 earnings per share for the current fiscal year.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.